Related Experiment Video
Updated: Feb 25, 2026
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology
Ilaria Colombo1, Marta Overchuk2, Juan Chen1
1Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
Abstract:
Despite the significant advancement achieved in understanding the molecular mechanisms responsible for cancer transformation and aberrant proliferation, leading to novel targeted cancer therapies, significant effort is still needed to "personalize" cancer treatment. Molecular imaging is an emerging field that has shown the ability to characterize in vivo the molecular pathways present at the cancer cell level, enabling diagnosis and personalized treatment of malignancies. These technologies, particularly SPECT and PET also permit the development of novel radiotheranostic probes, which provide capabilities for diagnosis and treatment with the same agent. The small therapeutic index of most anticancer agents is a limitation in the drug development process. Incorporation of molecular imaging in clinical research may help in overcoming this limitation and favouring selection of patient populations most likely to achieve benefit from targeted therapy. This review will focus on two of the most advanced theranostic approaches with promising potential for application in the clinic: 1) therapeutic monoclonal antibodies which may be linked to a radionuclide for SPECT or PET imaging to guide cancer diagnosis, staging, molecular characterization, and assessment of the response to treatment and 2) multifunctional nanotechnology that allows image guided drug delivery through encapsulation of multiple therapeutic, targeting and imaging agents into a single nanoparticle. Porphysome, a liposome-like nanoparticle, is an example of a novel and promising application of nanotechnology for cancer diagnosis and treatment. These technologies have proven to be effective in preclinical models, warranting further clinical investigation to advance their application for the benefit of cancer patients.
Insights
Molecular imaging advances personalized cancer treatment by enabling in vivo characterization of cancer cells. Theranostic probes, like radiolabeled antibodies and nanoparticles, offer combined diagnosis and therapy for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Imaging
- Nanotechnology
Background:
- Significant progress in understanding cancer molecular mechanisms has led to targeted therapies, yet personalization remains a challenge.
- Molecular imaging offers in vivo characterization of cancer cell pathways, crucial for personalized diagnosis and treatment.
- Radiotheranostic probes, combining diagnosis and therapy, are emerging to address the limitations of small therapeutic indices in anticancer agents.
Purpose of the Study:
- To review advanced theranostic approaches for personalized cancer diagnosis and treatment.
- To highlight the potential of molecular imaging in guiding targeted therapies and patient selection.
- To discuss the clinical promise of radiolabeled antibodies and nanotechnology-based drug delivery systems.
Main Methods:
- Focus on two key theranostic approaches: therapeutic monoclonal antibodies linked to radionuclides for SPECT/PET imaging, and multifunctional nanotechnology for image-guided drug delivery.
- Examines the use of radiolabeled antibodies for cancer diagnosis, staging, molecular characterization, and treatment response assessment.
- Discusses nanotechnology, exemplified by Porphysome, for encapsulating therapeutic, targeting, and imaging agents within nanoparticles.
Main Results:
- Theranostic probes, including radiolabeled antibodies and nanoparticles, demonstrate potential for integrated cancer diagnosis and therapy.
- Molecular imaging can guide the selection of patient populations likely to benefit from targeted therapies.
- Preclinical studies show the effectiveness of these theranostic technologies, supporting further clinical investigation.
Conclusions:
- Advanced theranostic approaches, particularly radiolabeled antibodies and nanotechnology, hold significant promise for personalized cancer care.
- Molecular imaging integrated into clinical research can overcome limitations of traditional anticancer drug development.
- Further clinical investigation is warranted to translate these promising preclinical findings into patient benefits.
